Abstract
In this issue of Blood, Collins et al provide the results of a prospective, randomized, single-blind, phase 3 trial on the use of nonacog beta pegol, a new long-acting glycoPEGylated factor IX (FIX) molecule for the treatment and prevention of bleeding episodes in 74 patients with hemophilia B.
| Original language | English |
|---|---|
| Pages (from-to) | 3836-3837 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 124 |
| Issue number | 26 |
| DOIs | |
| Publication status | Published - Dec 18 2014 |
ASJC Scopus subject areas
- Hematology
- Biochemistry
- Cell Biology
- Immunology
- Medicine(all)